EUVIMEDEUVIMED entdecken
Crossref

Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors

Ruirui Yang iD, Bei Wang iD, Zhaoming Su, Ying Song, Yingying Zhang, Yadan Liu, Yinghui Zhang, Changyu He, Xi Yang, Feisheng Zhong, Zunyun Fu, Yiluan Ding und 9 weitere

Science Translational Medicine · 04.06.2025 · 17 (801)

DOI: 10.1126/scitranslmed.adn6921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 04.06.2025. Verfasst von Ruirui Yang und 20 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub Lane Xiangsh…. Hauptthemen laut MEDLINE: Methotrexate, Immunotherapy, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-dose methotrexate (MTX) is the first-line drug for treating rheumatoid arthritis as an immunosuppressor. We have identified that low-dose MTX exhibits antitumor immune activity. MTX treatment reduced tumor metastasis and enhanced the efficacy of radiation therapy and immune checkpoint blockade therapy in mice. Mechanistically, MTX selectively induced DNA damage, cGAS-STING [cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) synthase (cGAS)–stimulator of interferon genes (STING)] pathway activation, and cGAMP generation in cancer cells. Furthermore, MTX bound to the substrate-binding pocket of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), inhibiting ENPP1-mediated cGAMP hydrolysis and adenosine generation. Consequently, MTX reduced extracellular adenosine and enhanced host STING-mediated antitumor immunity. In addition, a preliminary clinical trial demonstrated promising efficacy and safety of low-dose MTX in combination with immunotherapy and radiotherapy for patients with unresectable or metastatic solid tumors, showing improved outcomes compared with historical controls. These results highlight the previously unrecognized immunostimulatory functions of MTX and provide a rationale for combining MTX with tumor immunotherapy and radiotherapy in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateImmunotherapyNeoplasmsAntineoplastic AgentsAnimalsHumansMiceCell Line, TumorTreatment OutcomeFemalePhosphoric Diester HydrolasesNucleotides, CyclicMembrane ProteinsNucleotidyltransferasesDNA DamagePyrophosphatasesMale

Substanzen

MethotrexatePhosphoric Diester HydrolasesNucleotides, Cycliccyclic guanosine monophosphate-adenosine monophosphateMembrane ProteinsNucleotidyltransferasesAntineoplastic AgentsPyrophosphatases

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub Lane Xiangshan, Hangzhou 310024, China.
  • Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, Jiangsu, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, 443 Huangshan Road, Hefei 230026, Anhui, China.
  • Shanghai Key Laboratory of Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

ORCID-Profile: Ruirui Yang, Bei Wang, Naixia Zhang, Rui Li, Haiwei Shen, Wei Geng, Sulin Zhang, Mingyue Zheng

Zitieren

APA

Yang, R., Wang, B., Su, Z., Song, Y., Zhang, Y., Liu, Y., Zhang, Y., He, C., Yang, X., Zhong, F., Fu, Z., Ding, Y., Zhang, N., Li, R., Chu, S., Xu, C., Sun, J., Shen, H., Geng, W., …, & Zheng, M. (2025). Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors. Science Translational Medicine, 17(801). https://doi.org/10.1126/scitranslmed.adn6921

Vancouver

Yang R, Wang B, Su Z, Song Y, Zhang Y, Liu Y, et al. Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors. Science Translational Medicine. 2025;17(801). doi:10.1126/scitranslmed.adn6921

BibTeX
@article{Yang2025,
  author = {Yang, Ruirui and Wang, Bei and Su, Zhaoming and Song, Ying and Zhang, Yingying and Liu, Yadan and Zhang, Yinghui and He, Changyu and Yang, Xi and Zhong, Feisheng and Fu, Zunyun and Ding, Yiluan and Zhang, Naixia and Li, Rui and Chu, Shuqing and Xu, Chuanhai and Sun, Jian and Shen, Haiwei and Geng, Wei and Zhang, Sulin and Zheng, Mingyue},
  title = {Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {801},
  doi = {10.1126/scitranslmed.adn6921}
}
Kostenlos starten →